| (S)-SLV 319CB1 receptor antagonist |

Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.
Nature.2018 Jun 13.
Nature.2018 Jun 27.
Nature.2018 Mar 29;555(7698):673-677.
Nature.2017 Sep 7;549(7670):96-100.
Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8
Nat Nanotechnol.2017 Dec;12(12):1190-1198.
Nature Biotechnology.2017 Jun;35(6):569-576
Nat Med.2018 Sep 17.
Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.
Cell.Available online 25 October 2018.
Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.
Cell.2018 Jun 28;174(1):172-186.e21.
Cell.2018 Feb 22;172(5):1007-1021.e17.
Cell.2017 Nov 30;171(6):1284-1300.e21.
Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.
Cell.2017 Jul 13;170(2):312-323
Nat Med.2018 Jan 29.
Nat Med.2017 Nov;23(11):1342-1351.
Cell.2017 Apr 6;169(2):286-300.
Cell.2015 Aug 27;162(5):987-1002.
Cell.2015 Feb 12;160(4):729-44.
Nature Medicine.2017 Apr;23(4):493-500.
Cancer Cell.2018 May 14;33(5):905-921.e5.
Cancer Cell.2018 Apr 9;33(4):752-769.e8.
Cancer Cell.2018 Mar 12;33(3):401-416.e8.
Cancer Cell.2017 Aug 14;32(2):253-267.e5.
Nat Methods.2018 Jul;15(7):523-526.
Cell Stem Cell.2018 May 3;22(5):769-778.e4.
Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure


(S)-SLV 319 Dilution Calculator
calculate

(S)-SLV 319 Molarity Calculator
calculate
| Cas No. | 464213-10-3 | SDF | Download SDF |
| Synonyms | Ibipinabant|BMS 646256|JD 5001 | ||
| Chemical Name | 3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N"-methyl-4S-phenyl-1H-pyrazole-1-carboximidamide | ||
| Canonical SMILES | C/N=C(NS(=O)(=O)c1ccc(Cl)cc1)/N1N=C(c2ccc(Cl)cc2)C(C1)c1ccccc1 | ||
| Formula | C23H20Cl2N4O2S | M.Wt | 487.4 |
| Solubility | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Ki: 7.8 and 7,9 nM for CB1 and peripheral cannabinoid (CB2), respectively
(S)-SLV 319 is a CB1 receptor antagonist.
It has been reported that central cannabinoid (CB1) receptor antagonists may have potential in the treatment of a variety of diseases including cognitive disorders, neuro-inflammatory disorders, obesity, septic shock, psychosis, addiction, as well as gastrointestinal disorders.
In vitro: Previous study found that (S)-SLV 319 was a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,9 nM for CB1 and CB2, respectively. In addition, (S)-SLV 319 was found to be less lipophilic and thus more water soluble than other previously identifiedligands of CB1 receptor [1].
In vivo: Previous animal study showed that in rats exposed to an ambient temperature of 22°c, a moderate dose of LPS at 25 - 100 μg/kg could induce a fall in body temperature. Such response was not affected by desensitization of intra-abdominal TRPV1 receptors with resiniferatoxin at 20 μg/kg, by systemic TRPV1 antagonism with capsazepine at 40 mg/kg, or by systemic CB2 receptor antagonism with SR144528 at 1.4 mg/kg. In contrast, CB1 receptor antagonism by SLV319 at 15 mg/kg or rimonabant at 4.6 mg/kg was able to block LPS caused hypothermia [2].
Clinical trial: So far, no clinical study has been conducted.
References:[1] J. H. M. Lange, H. H. van Stuivenberg, W. Veerman, et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorganic & Medicinal Chemistry Letters 15, 4794-4798 (2005). [2] Steiner AA et al. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol. 2011 May 1;589(Pt 9):2415-31.


